Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

Autor:	Daniel P. Silver, Weelic Chong, Geetha Jagannathan, Frederick M. Fellin, Kaelan Yao, Terrence P. Cescon, Maysa M. Abu-Khalaf, Chun Wang, Zhaomei Mu, Brian Lu, Manish Neupane, Ana Maria Lopez, Adam C. Berger, Rebecca Jaslow, Massimo Cristofanilli, Saveri Bhattacharya, Ronald E. Myers, Zhenchao Zhang, Qiang Wei, Bingshan Li, Zhong Ye, Theodore N. Tsangaris, Hushan Yang, Lifang Hou, Juan P. Palazzo
Rok vydání:	2020
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Article Targeted therapy 03 medical and health sciences 0302 clinical medicine Circulating tumor cell Breast cancer Internal medicine Biomarkers Tumor Medicine Humans Neoplasm Staging business.industry Proportional hazards model Advanced stage Hazard ratio HER2 negative Middle Aged medicine.disease Neoplastic Cells Circulating Confidence interval Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Female business
Zdroj:	Breast Cancer Res Treat
ISSN:	1573-7217
Popis:	PURPOSE: Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2(−)/cHER2(+) can benefit from anti-HER2 targeted therapies. METHODS: cHER2 status was determined in 105 advanced-stage patients with tHER2(−) breast tumors. Association between cHER2 status and progression-free survival (PFS) was analyzed by univariate and multivariate Cox models and survival differences were compared by Kaplan-Meier method. RESULTS: Compared to the patients with low-risk cHER2 (cHER2(+)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abde5f647252f168f9f5b30bb7a065dc https://pubmed.ncbi.nlm.nih.gov/32367460 Zobrazit plný text záznamu Full text from SpringerLink